Jan H M Schellens
Overview
Explore the profile of Jan H M Schellens including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
536
Citations
15545
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rollema H, Volkmann R, Zagouras P, Nelson F, Braish T, Marfat A, et al.
Int J Pharm
. 2025 Feb;
672:125317.
PMID: 39909155
LB-100, a small molecule PP2A inhibitor currently in phase 1 and 2 dose-finding and efficacy trials, is an amide that is stable at pH ≥ 10.5, but can hydrolyze at...
2.
Knikman J, Zhai Q, Lunenburg C, Henricks L, Bohringer S, van der Lee M, et al.
Genome Med
. 2024 Aug;
16(1):101.
PMID: 39148102
Background: The Alpe-DPD study (NCT02324452) demonstrated that prospective genotyping and dose-individualization using four alleles in DPYD (DPYD*2A/rs3918290, c.1236G > A/rs75017182, c.2846A > T/rs67376798 and c.1679 T > G/rs56038477) can mitigate...
3.
Embaby A, Huijberts S, Wang L, Leite de Oliveira R, Rosing H, Nuijen B, et al.
Clin Cancer Res
. 2024 May;
30(15):3157-3166.
PMID: 38739109
Purpose: The development of resistance limits the clinical benefit of BRAF and MEK inhibitors (BRAFi/MEKi) in BRAFV600-mutated melanoma. It has been shown that short-term treatment (14 days) with vorinostat was...
4.
Le Teuff G, Cozic N, Boyer J, Boige V, Diasio R, Taieb J, et al.
Br J Cancer
. 2024 Jan;
130(5):808-818.
PMID: 38225422
Background: Dihydropyrimidine dehydrogenase (DPD) deficiency is the main known cause of life-threatening fluoropyrimidine (FP)-induced toxicities. We conducted a meta-analysis on individual patient data to assess the contribution of deleterious DPYD...
5.
Knikman J, Lopez-Yurda M, Meulendijks D, Deenen M, Schellens J, Beijnen J, et al.
Clin Pharmacol Ther
. 2023 Nov;
115(2):269-277.
PMID: 37957132
DPYD-guided dosing has improved the safety of fluoropyrimidine-based chemotherapy in recent years. However, severe toxicity remains in ~ 23% of patients not carrying DPYD variant alleles treated with capecitabine. Therefore,...
6.
Knikman J, Wilting T, Lopez-Yurda M, Henricks L, Lunenburg C, de Man F, et al.
J Clin Oncol
. 2023 Aug;
41(35):5411-5421.
PMID: 37639651
Purpose: -guided fluoropyrimidine dosing improves patient safety in carriers of variant alleles. However, the impact on treatment outcome in these patients is largely unknown. Therefore, progression-free survival (PFS) and overall...
7.
Subbiah V, Kreitman R, Wainberg Z, Gazzah A, Lassen U, Stein A, et al.
Nat Med
. 2023 Apr;
29(5):1103-1112.
PMID: 37059834
BRAFV600E alterations are prevalent across multiple tumors. Here we present final efficacy and safety results of a phase 2 basket trial of dabrafenib (BRAF kinase inhibitor) plus trametinib (MEK inhibitor)...
8.
Postel-Vinay S, Lam V, Ros W, Bauer T, Hansen A, Cho D, et al.
J Immunother Cancer
. 2023 Mar;
11(3).
PMID: 36927527
Background: The phase I first-in-human study ENGAGE-1 evaluated the humanized IgG1 OX40 agonistic monoclonal antibody GSK3174998 alone (Part 1 (P1)) or in combination with pembrolizumab (Part 2 (P2)) in patients...
9.
de With M, Knikman J, Schellens J, Gelderblom H, Cats A, Guchelaar H, et al.
Clin Pharmacol Ther
. 2022 Nov;
113(3):473-475.
PMID: 36352517
No abstract available.
10.
Schmidt K, Karzai F, Bilusic M, Cordes L, Chau C, Peer C, et al.
Oncologist
. 2022 May;
27(9):718-e694.
PMID: 35640474
Background: Despite the clinical efficacy of enzalutamide monotherapy in patients with advanced prostate cancer, therapeutic resistance and disease progression are inevitable. We proposed a study to evaluate NLG207, a nanoparticle-drug...